TCA
SRPT icon

Transcend Capital Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Transcend Capital Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,000
Closed -$229K – 510
2023
Q2 		$229K Buy
+2,000
New +$258K 0.02% 430

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Transcend Capital Advisors's SRPT Position: Q3 2023 in Review

Transcend Capital Advisors sold out of Sarepta Therapeutics (SRPT) in Q3 2023, closing a stake of 2,000 shares — an estimated $229K sold.

Transcend Capital Advisors first reported a position in SRPT in Q2 2023 and held it in 1 quarter. The position peaked at $229K in Q2 2023. 394 funds tracked by Wall St. Rank hold SRPT as of Q3 2023.

  • Transcend Capital Advisors reported no remaining Sarepta Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Transcend Capital Advisors sold 2,000 Sarepta Therapeutics shares in Q3 2023, an estimated $229K.
  • Transcend Capital Advisors first reported a position in Sarepta Therapeutics in Q2 2023 and held it in 1 quarter.
  • Transcend Capital Advisors's Sarepta Therapeutics position peaked at $229K in Q2 2023.
  • 394 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2023.

Based on Transcend Capital Advisors's 13F filing for Q3 2023, filed 31 Oct 2023.